XLIF® vs. MAS®TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis.
- Conditions
- Spondylolisthesis
- Registration Number
- NCT01024699
- Lead Sponsor
- NuVasive
- Brief Summary
The purpose of this study is to determine differences in the XLIF and TLIF procedures with respect to perioperative variables in adult patients with low-grade symptomatic spondylolisthesis.
- Detailed Description
The study is a prospective multi-center randomized evaluation of clinical and radiographic outcomes of two commonly used lumbar interbody fusion procedures (XLIF and TLIF) in adult patients with low-grade symptomatic spondylolisthesis. The study seeks to identify differences between the procedures with respect to perioperative variables.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 55
-
Male and female patients who are at least 18 years of age;
-
Patients who present with symptomatic Grade I or II degenerative spondylolisthesis at 1 or 2 contiguous lumbar levels between L1 and L5 and are surgical candidates for interbody lumbar fusion surgery; symptoms should include radiculopathy and/or neurogenic claudication with or without back pain;
-
Patients who have been unresponsive to at least 6 months of conservative treatments or exhibit progressive neurological symptoms in the face of conservative treatment;
-
Patients who understand the conditions of enrollment and are willing to sign an informed consent to participate in the study.
-
Patients with lumbar pathologies requiring treatment at more than 2 levels;
-
Patients who have had previous lumbar fusion surgery;
-
Patients with lytic spondylolisthesis or a defect of the pars interarticularis;
-
Patients with radiographic confirmation of Grade IV facet joint disease or degeneration;
-
Patients with non-contained or extruded herniated nucleus pulposus
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The average improvement in clinical function (ODI) at 24 months compared with baseline, for each procedure. 24 months
- Secondary Outcome Measures
Name Time Method The average improvement in pain (VAS) at 24 months compared with baseline, for each procedure. 24 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (8)
St. Vincent-Jacksonville
🇺🇸Jacksonville, Florida, United States
Celebration Florida Hospital
🇺🇸Kissimmee, Florida, United States
St. Joseph's/Candler Health System
🇺🇸Savannah, Georgia, United States
Northwest Orthopaedic Specialists, P.S.
🇺🇸Spokane, Washington, United States
Orthopaedic Clinic-Riverside Campus, University of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
The Methodist Hospital
🇺🇸Houston, Texas, United States
Spine and Sports Institute
🇺🇸Richland, Washington, United States
St. Vincent-Jacksonville🇺🇸Jacksonville, Florida, United States